ISCHEMIC HEART DISEASE PREVAILS as the leading cause of morbidity and mortality in Western societies (24) . During ischemia-reperfusion (I/R), cardiomyocytes undergo apoptosis and necrosis, which significantly compromise myocardial functional performance. Although these responses involve separate pathways, they share common mediators, allowing cross talk under certain conditions. In particular, mitochondrial membrane damage plays an important role in initiating apoptosis and necrosis (7, 9, 23, 34, 38, 53) . Upon mitochondrial injury, the abundance of ATP favors the execution of apoptotic cardiomyocyte death; however, necrosis ensues under circumstances of impaired cellular energy status (7, 10, 20, 45) .
Principal regulators of mitochondrial membrane integrity and function include the Bcl-2 protein family, which consists of three subgroups distinguished by structural homology. The antiapoptotic subgroup entails, among others, Bcl-2 and Bclx L , which protect the mitochondrial membranes by interacting with and inhibiting the proapoptotic subgroup of effectors Bax and Bak (7-9, 48, 60) . The BH3-only proteins (BH: Bcl-2 homology) represent the third subgroup (e.g., Nix, BNIP3, Bad, Bid, Noxa, and Puma) and share sequence homology with other Bcl-2-like proteins only in the BH3 region (40) . They use this region to heterodimerize with Bcl-2/Bcl-x L , thereby releasing Bax/Bak, which then form homodimers and trigger cytochrome c release and caspase activation (7, 8, 40) .
These characteristics of the Bcl-2 family members offer an intriguing rationale to protect the heart from I/R injury by upregulating antiapoptotic or repressing proapoptotic proteins. In agreement with this hypothesis, elevated expression of Bcl-2 or Bcl-x L , or ablation of Bax, promotes recovery from cardiac I/R injury (5, 18 -20) . Among the BH3-only proteins, Nix and BNIP3 have recently been implicated in cardiomyocyte death (14, 26, 58) ; however, little is known regarding the contribution of other BH3-only proteins to cardiac diseases. Puma (p53 upregulated modulator of apoptosis) is a recently identified BH3-only protein that binds Bcl-2 and Bcl-x L and induces apoptosis in a p53-dependent (DNA damage, hypoxia, or oncogenes) and -independent (serum withdrawal, glucocorticoids, kinase inhibitors, or phorbol esters) manner (15, 21, 37, 49, 56) . Given the requirement for Puma to integrate and implement a number of diverse death signals, we hypothesized that Puma may contribute to cardiomyocyte death upon I/R injury.
In the present study, we have demonstrated that hypoxiareoxygenation induces Puma expression in cultured cardiomyocytes and intact hearts. Consistent with this finding, targeted deletion of Puma significantly improved the tolerance of isolated mouse hearts to I/R by preventing apoptotic and necrotic cell death. Puma, therefore, appears to be a novel therapeutic target in ischemic heart disease.
MATERIALS AND METHODS

Isolation of primary cardiomyocytes and adenoviral infections.
Neonatal cardiomyocytes were prepared using a Percoll gradient method as described elsewhere (50) . Briefly, neonatal hearts from 1-to 2-day-old Sprague-Dawley rats were cut into three or four equalsized pieces and digested in enzyme solutions [collagenase type II (Worthington Biochemicals) and pancreatin (Sigma)]. The enzymes were inactivated by addition of newborn calf serum, and the released cells were pooled and separated on a discontinuous Percoll gradient (top density ϭ 1.059 g/ml, bottom density ϭ 1.082 g/ml) by centrif-ugation. The middle band at the interface of the two Percoll layers was collected. The cells were then plated onto gelatin-coated dishes or laminin-coated glass coverslips at a density of 1 ϫ 10 5 cells/cm 2 and cultured in serum-containing medium (4:1 DMEM-medium 199, 10% horse serum, 5% fetal bovine serum, 100 U/ml penicillin, 100 g/ml streptomycin, and 10 mM glutamine) for 2 days. To prevent proliferation of nonmyocyte contamination, 0.2 mM bromodeoxyuridine was added to the culture medium.
Adenoviruses were purified by cesium chloride banding and titrated using the Adeno-X Rapid Titer kit (Clontech Laboratories). Adenoviral infection (multiplicity of infection ϭ 10 -50 plaqueforming units/cell) was performed in glucose-containing (ATP-repleted) or glucose-free (plus 1 M oligomycin, ATP-depleted) DMEM containing Nutridoma and 5% horse serum (10, 45) for the indicated times. Wild-type (AdPuma) and BH3 domain-defective mutant Puma-␣ (Ad⌬BH3) adenoviral constructs were kindly provided by Dr. Jian Yu (55) .
In vitro model of hypoxia-reoxygenation. At 2 days after isolation, neonatal rat cardiomyocytes were cultured in serum-and glucose-free DMEM under hypoxic conditions as described elsewhere (57) , with some modifications. Hypoxia was achieved by incubation of cells in a humidified environment at 37°C in a three-gas incubator maintained at 5% CO 2 and 1% O2 for the indicated times. Subsequently, half of the samples were reoxygenated for 16 h in maintenance medium. After hypoxia or hypoxia-reoxygenation, the samples were processed for RT-PCR or immunoblot analysis.
Semiquantitative RT-PCR. RNA was isolated from cardiomyocytes using TRIzol reagent (Invitrogen) and processed according to the manufacturer's instructions. RT was performed with the iScript cDNA synthesis kit (Bio-Rad) using 1 g of total RNA, and semiquantitative PCR was carried out using the following Puma primers: 5Ј-ATG-GCGGACGACCTCAAC-3Ј (forward) and 5Ј-AGTCCCATGAA-GAGATTGTACATGAC-3Ј (reverse). GAPDH served as a loading control.
Immunoblot analysis. Immunoblot analysis was performed as described elsewhere (11) . Briefly, cells or heart tissues were lysed in radioimmunoprecipitation assay buffer complemented with protease inhibitors. Protein samples (10 -20 g) were electrophoresed in 12% denaturing SDS-polyacrylamide gels and transferred onto nitrocellulose membranes. The membranes were incubated with blocking buffer (2% BSA in Tris-buffered saline-Tween 20) and then with primary antibodies specific for Puma-␣ NT (Imgenex), Bcl-2, Bax (Santa Cruz Biotechnology), actin (Sigma), procaspase-3 (Pharmingen), cleaved caspase-3 or Bcl-xL (Cell Signaling Technology), and, finally, horseradish peroxidase-conjugated secondary antibodies. Protein bands were visualized with the SuperSignal chemiluminescence detection system (Pierce).
Immunocytochemistry. Immunocytochemistry methods have been described previously (12) . Briefly, cardiomyocytes were grown on laminin-coated glass coverslips and fixed with 3.7% formaldehyde (in 1ϫ PBS) for 10 min. The cells were permeabilized with 0.5% Triton X-100 in 1ϫ PBS for 5 min, incubated in blocking buffer (5% goat serum and 1% BSA in 1ϫ PBS), and then probed with primary and secondary antibodies in blocking buffer. The coverslips were mounted, and the images were analyzed by confocal fluorescence microscopy (Bio-Rad). Apoptotic cells were detected by the TdTmediated dUTP in situ nick-end labeling (TUNEL) method (Roche). Sections were costained with anti-sarcomeric actinin (Sigma). Irreversible membrane damage was assessed by staining cells with ethidium homodimer-2 (EH-2) and SYTO 10 (Molecular Probes).
Langendorff mouse heart perfusion. We used a system purchased from ADInstruments (46) to adapt the heart perfusion protocol, which we published earlier for rats, to mice. Puma-deficient mice were generated on a C57BL/6-129SvJ mixed background as described earlier (21) . Mice (7-10/group, 20 -30 g body wt) were anesthetized with pentobarbital sodium (60 mg/kg ip), and the hearts were rapidly excised and placed into ice-cold Krebs-Henseleit buffer and then retrogradely perfused at a constant pressure (80 mmHg) at a flow rate of 1-3 ml/min. The perfusion buffer was a modified phosphate-free Krebs-Henseleit buffer that contained (in mM) 118 NaCl, 4.7 KCl, 2 CaCl2, 1.2 MgSO4, 25 NaHCO3, and 11 glucose. The perfusate was equilibrated at 37°C with 95% O2-5% CO2 through a glass oxygenator to achieve pH 7.4. The hearts were exposed to a 20-min baseline perfusion and then subjected to 20 min of no-flow ischemia and subsequently reperfused for 120 min. Hearts were paced at 7 Hz through platinum wires placed on the epicardial surface of the right ventricle; however, the pacer was turned off during ischemia. To measure left ventricular function, a small custom-made polyvinylchloride balloon was inserted into the left ventricle through the mitral valve and filled to achieve an end-diastolic pressure of 8 -12 mmHg. Functional data of mouse hearts [left ventricular developed pressure (LVDP), maximum rate of left ventricular pressure rise and fall (dP/dt max and dP/dtmin, respectively), and left ventricular end-diastolic pressure (LVEDP)] were monitored throughout the entire perfusion using a data acquisition system (PowerLab, ADInstruments). All animal protocols were approved by the Institutional Animal Care and Use Committee.
For determination of the infarct size, 2-mm-thick slices of the ventricles were immersed into 1% triphenyltetrazolium chloride (TTC; TCI America) or 1% nitro blue tetrazolium chloride (NBT; Amersham) solution in phosphate buffer at 37°C for 20 min (25, 31, 32) . For detection of membrane damage, coronary effluent was collected during baseline perfusion and reperfusion for measurement of lactate dehydrogenase (LDH) activity (US Biological). Apoptotic cells were detected by the TUNEL method on immunohistological samples. Sections were costained with anti-sarcomeric actinin. Images were analyzed by confocal fluorescence microscopy.
RESULTS
Hypoxia-reoxygenation leads to increased Puma mRNA and protein levels in isolated cardiomyocytes.
Because Puma is required for hypoxia-induced apoptosis of colorectal cancer cells and is transcriptionally upregulated by I/R in hippocampal cells (42, 55) , we hypothesized that Puma might contribute to the hypoxia-reoxygenation-induced apoptosis described earlier in cardiac cells (1, 4, 13, 34, 44, 59) . First, using semiquantitative RT-PCR, we investigated the possibility that hypoxiareoxygenation induces Puma mRNA expression in primary rat cardiomyocytes. Puma mRNA levels were increased after 2 h of hypoxia and remained higher than in the control sample for up to 8 h (Fig. 1A) . We also observed enhanced Puma expression when a 2-or 4-h period of hypoxia was followed by reoxygenation, but Puma mRNA levels returned to baseline in the 8-h hypoxia-reoxygenation sample (Fig. 1A) .
Next, we determined whether expression of Puma mRNA is translated into increased protein levels in cardiac cells. To carry out these studies, we used an anti-Puma antibody that was raised against an NH 2 -terminal peptide sequence identical in mouse, rat, and human (Imgenex). The antibody detected a single adriamycin-inducible band in Puma-positive, but not Puma-negative, HCT116 colorectal cancer cells, demonstrating the specificity of this antibody (data not shown). After exposing cardiomyocytes to hypoxia or hypoxia-reoxygenation, we observed a significant increase in Puma protein levels compared with those of the control sample (Fig. 1B) . Importantly, the time course of Puma protein induction was consistent with that of Puma mRNA expression.
In summary, Puma expression is triggered upon hypoxiareoxygenation of cardiomyocytes; therefore, it might contribute to hypoxia-reoxygenation-induced cardiac cell death.
Isolated cardiomyocytes undergo apoptosis in response to ectopic Puma expression.
To evaluate whether Puma induces apoptosis in cardiac cells, cardiomyocytes were infected with adenoviruses expressing a wild-type Puma-␣ protein, and apoptosis was scored by TUNEL assay. A low level of exogenous Puma expression and concomitant apoptosis were first apparent at 6 h after infection (Fig. 2) . By 12 h, there was a marked increase in Puma protein, resulting in ϳ50% apoptosis (Fig. 2) . By 24 h, a further increase in Puma expression was accompanied by Ͼ80% TUNEL positivity (Fig. 2) . As a negative control, we infected cardiomyocytes with a virus encoding a BH3-deletion mutant Puma-␣ (⌬BH3). The mutant Puma ⌬BH3 adenovirus resulted in higher Puma expression than the wild-type infection but did not lead to apoptosis, indicating that the adenovirus infection by itself was not sufficient to induce apoptosis (Fig. 2) . Taken together, overexpression of Puma leads to cardiomyocyte apoptosis in a BH3-domain-dependent manner.
ATP depletion converts Puma-induced cardiomyocyte apoptosis to necrosis. In cultured cardiomyocytes, Puma predominantly induces apoptosis ( Fig. 2A) , but myocardial injury after I/R results in both apoptosis and necrosis (1, 3, 16) . Therefore, if Puma plays a role in cardiac I/R, the apoptotic events triggered by its overexpression may be reverted to necrosis. To test this possibility, we analyzed the response of cardiomyocytes infected with Puma adenoviruses to ATP-depleted conditions.
Because of the time course of Puma expression and apoptosis (Fig. 2) , we focused on 12-h virus infection, when extensive Puma-induced apoptosis was first observed, and determined the activity of caspase-3 as a hallmark of apoptosis. Infection with wild-type Puma adenovirus in the presence of glucose (and ATP) caused significant caspase-3 activation and apoptosis. This has been demonstrated by an increase in the proteolytically cleaved species of caspase-3, with a concomitant decrease of the noncleaved inactive form as shown by Western blot analysis (Fig. 3A) . The same wild-type Puma infection in the absence of ATP (1 M oligomycin in glucosefree medium over 3 h), however, did not lead to caspase-3 cleavage (Fig. 3A) . The BH3-domain-defective Puma virus, which served as a negative control, did not trigger caspase-3 cleavage in any of the conditions (Fig. 3A) . As expected, ATP depletion prevented activation of the apoptotic cascade by Puma.
We subsequently determined whether Puma induced necrosis, instead of apoptosis, in cardiomyocytes under ATP-depleting conditions. To analyze the extent of necrosis, we used EH-2 staining to assess the fraction of cells with membrane damage (Fig. 3B) . A small but significant increase (ϳ3-fold) in EH-2 staining was observed in wild-type Puma-expressing cells in the presence of ATP at 12 h after infection (Fig. 3, B  and C) . Because half of these cells are TUNEL positive (Fig.  2, B and C) , a substantial percentage might represent late apoptotic cells with membrane damage. Similarly, expression of the ⌬BH3 mutant in conjunction with ATP depletion slightly increased the number of EH-2-positive nuclei (Fig. 3,  B and C) . In sharp contrast, wild-type Puma expression combined with ATP depletion resulted in Ͼ80% EH-2 positivity (Fig. 3, B and C) . Because these cells did not undergo apoptosis (Fig. 3A) , the decreased viability corresponds to caspaseindependent necrotic cell death. These results demonstrate that Puma can trigger necrosis, rather than apoptosis, when ATP stores are limiting.
In summary, our findings indicate that Puma induces apoptosis in the presence of ATP, whereas it causes necrosis in ATP-depleted cells. Therefore, Puma might be a causal factor in cardiac cell death during I/R.
Puma deletion improves cardiac function and protects cardiomyocytes from cell death in isolated perfused hearts. To assess the role of Puma in cardiac I/R in intact hearts, we first examined whether Puma is induced upon I/R of isolated mouse hearts. Similar to our findings in response to hypoxia-reoxygenation (Fig. 1) , Puma protein level was increased after 20 min of ischemia and remained elevated during postischemic reperfusion (Fig. 4A) . Subsequently, we generated a Pumaknockout mouse line and compared the functional performance of Langendorff-perfused hearts of wild-type, Puma ϩ/Ϫ , and Puma Ϫ/Ϫ mice. Most importantly, we found a strikingly better postischemic functional recovery in hearts of Puma-knockout mice than in hearts of wild-type or heterozygous animals. No significant differences were observed in the baseline parameters of the animals, regardless of their genotype (Table 1) . After 20 min of no-flow ischemia and 120 min of reperfusion, the LVDP, dP/dt max , and dP/dt min of wild-type hearts recovered only to 15 Ϯ 3, 11 Ϯ 3, and 11 Ϯ 3% of their baseline values, respectively (Fig. 4, B-D) . In sharp contrast, functional recovery of Puma Ϫ/Ϫ hearts dramatically improved, with LVDP, dP/dt max , and dP/dt min reaching 73 Ϯ 12, 77 Ϯ 14, and 67 Ϯ 14% of their baseline values, respectively, after 120 min of reperfusion (Fig. 4, B-D) . The recovery did not differ between hearts heterozygous for Puma and their wild-type littermates (Fig. 4, B-D) , indicating that reduced amounts of Puma protein are sufficient to exert prodeath activities. In accordance with the robust and significantly better recovery of LVDP, dP/dt max , and dP/dt min in Puma Ϫ/Ϫ hearts, LVEDP was also consistently lower in Puma Ϫ/Ϫ hearts during reperfusion than in their wild-type and heterozygous littermates: at the end of 120 min of reperfusion, LVEDP was 9 Ϯ 1.9 and 37 Ϯ 2.8 mmHg in Puma Ϫ/Ϫ and wild-type hearts, respectively (Fig. 4E ). Because cell loss is a major contributor to I/R-induced cardiac injury, we analyzed the effect of Puma deletion upon I/R-induced necrosis and apoptosis in isolated perfused hearts. To measure necrosis, we determined the extent of the infarcted area by TTC as well as NBT staining in histological sections and measured LDH release in the coronary effluent. In the TTC and NBT assays, Ͼ50% of the myocardium became infarcted upon I/R in wild-type and heterozygous hearts. By contrast, deletion of Puma reduced the infarct size to half that of the wild-type control (27 and 22% by TTC and NBT assays, respectively; Fig. 5A ). Consistent with the infarct size assays, release of LDH into the perfusion fluid was also significantly decreased by ϳ50% in Puma Ϫ/Ϫ compared with wild-type and heterozygous hearts (Fig. 5B) . These results indicate that Puma is an important mediator of necrosis after cardiac I/R.
To measure apoptosis, we scored the TUNEL-positive cardiomyocytes in immunohistological sections. After 2 h of postischemic reperfusion, ϳ1% of the cells underwent apoptosis in wild-type as well as heterozygous hearts (Fig. 5C ). This level of cell death is equivalent to a Ͼ10-fold increase com- pared with the normoxic control and is in agreement with previous reports (22, 34, 54) . Importantly, in Puma-knockout hearts, the degree of apoptosis was significantly reduced to ϳ0.3% (Fig. 5C) .
Finally, we observed no change in the protein levels of several other Bcl-2 family members, including Bcl-2, Bcl-x L , and Bax, in Puma Ϫ/Ϫ hearts (Fig. 5D ). Therefore, it seems very unlikely that the improved tolerance of Puma Ϫ/Ϫ hearts to I/R injury stemmed from altered expression of other Bcl-2 family proteins. Collectively, these findings establish Puma as a crucial mediator of I/R-induced myocardial dysfunction and cell death.
DISCUSSION
In the present report, we have identified the BH3-only Bcl-2 family protein Puma as an essential mediator of cardiomyocyte death in response to I/R injury. In recent studies, Puma has emerged as a critical regulator of cell death in cancer, acquired immunodeficiency syndrome, and ischemic brain disease and has attracted considerable interest for several reasons (37, 39, 42, 56) . 1) Puma is crucial for p53-dependent and -independent apoptosis (15, 21, 37, 49, 56) . It is regarded as a major and specific apoptotic effector of p53, because Puma deficiency almost completely suppresses p53-dependent apoptosis but does not impair nonapoptotic functions (21, 49, 56) . 2) Puma activation is regulated by multiple transcription factors, such as p53, p73, and E2F1, providing the molecular basis for a potential differential regulation of Puma expression (17, 35, 37, 55) . 3) Puma activates its downstream apoptotic effectors Bax and Bak through binding to Bcl-2 or Bcl-x L . Thereby, Bax and Bak are released from inhibition and undergo homooligomerization, resulting in release of cytochrome c from mitochondria (28, 35) . 4) Puma induction directly links the endoplasmic reticulum stress response to the mitochondrial apoptosis pathway in neurons during postischemic reperfusion of the forebrain (42) .
Our most important observation is that targeted deletion of Puma rendered Langendorff-perfused mouse hearts resistant to I/R injury. During reperfusion of Puma Ϫ/Ϫ hearts, systolic and diastolic functions recovered close to their preischemic levels. Puma ablation improved postischemic functional recovery even better than Bax deletion and Bcl-2/Bcl-x L overexpression in other studies (5, 18 -20) . This might be the result of the upstream position of Puma in the regulatory network of Bcl-2 family proteins. For example, Puma exerts its effect through Bax and Bak (52, 60) ; therefore, in Bax Ϫ/Ϫ cells, Bak may still transmit the prodeath signals. Furthermore, Puma ϩ/Ϫ and wildtype hearts responded similarly after I/R, suggesting that even reduced levels of Puma might be sufficient to induce cell death. Values are means Ϯ SE. Data were obtained after 20 min of baseline perfusion from hearts paced at 7 Hz. LVDP, left ventricular (LV) developed pressure; dP/dtmax and dP/dtmin, maximum rate of LV pressure rise and fall, respectively; LVEDP, LV end-diastolic pressure.
Thymocytes and neuronal cells from Puma ϩ/Ϫ mice, however, displayed an intermediate apoptotic response upon ␥-irradiation (21) , implying that cardiomyocytes might be more sensitive to Puma than some other cell types. Alternatively, the different sensitivity of cells to Puma in the above experiments might also reflect stress stimulus-specific responses.
The improved functional recovery of Puma-knockout hearts most probably derived from decreased cardiomyocyte loss due to an alleviation of both apoptosis and necrosis. Consistent with this possibility, we found reduced levels of apoptosis by TUNEL assay and suppression of necrosis by measurement of infarct size and LDH release. In the Langendorff perfusion model, however, the contribution of necrosis to myocardial cell loss exceeds that of apoptosis (22, 34, 54) . Therefore, it appears that, in the Langendorff model, deletion of Puma protects the heart against I/R predominantly by blocking necrosis. This is further supported by our in vitro observation suggesting that Puma induces necrosis under ATP-depleted conditions, which represent a consequence of ischemia. Our data imply that the switch between necrosis and apoptosis described earlier upon ATP depletion (45, 47) occurs downstream of Puma.
Although our studies indicate that Puma expression is induced in hypoxic cardiomyocytes and ischemic hearts and is required for cell death during I/R, the regulation of Puma activity is not completely understood. In all cell types investigated thus far, Puma is transcriptionally upregulated during apoptosis (15, 28, 35, 37, 42, 55) , and p53 has been identified as a major upstream regulator (37, 55) . However, the role of p53 in heart ischemia remains somewhat controversial. Earlier studies reported that p53 is dispensable for hypoxia-induced cardiomyocyte apoptosis (2, 51) , whereas more recent studies demonstrated that p53 was induced by hypoxia-reoxygenation and I/R (27, 29, 30, 33, 36, 41) . Moreover, treatment with the p53 inhibitor pifithrin-␣ attenuated the I/R-induced infarct size similarly to ischemic preconditioning (36) . We also observed a slight improvement of functional recovery upon I/R in p53-negative mice (data not shown), suggesting that, to some extent, p53 might contribute to I/R injury in the heart. In light of the remarkable resistance of Puma-knockout hearts to I/R (Figs. 4 and 5) , it is most likely that transcription factors other than p53 play a role in Puma activation in cardiomyocytes. In recent studies, p73 and E2F1 have been described as activators of Puma transcription and as possible alternatives to p53 (17, 35) . Additional studies are needed to determine the contribution of p73 and E2F1, as well as other factors, to the regulation of Puma expression in the heart during I/R.
Although hypoxia-reoxygenation has been demonstrated to induce primarily p53-independent apoptosis (2, 51), genotoxic stress-induced cardiomyocyte apoptosis is predominantly dependent on p53 (36, 43) . Therefore, it is less likely that a recently reported dynamic interaction of Bcl-x L with p53 and Puma described upon genotoxic stress of cancer cells (6) plays a significant role in hypoxia-reoxygenation-induced cardiomyocyte apoptosis. Consistent with this, we did not detect p53 or Puma in Bcl-x L immunoprecipitates of cardiomyocytes exposed to hypoxia-reoxygenation (data not shown).
In recent reports, BNIP3, another BH3-only protein, has been implicated in the pathomechanism of I/R. It was shown that overexpression of BNIP3 by transcriptional activation upon hypoxia leads to cardiomyocyte death and, conversely, that downregulation of BNIP3 using antisense oligonucleotides protects isolated cardiomyocytes from hypoxia-induced death (14, 26) . Although Puma and BNIP3 belong to the same subset of the Bcl-2 family and are activated with a similar time course, their mechanism of action is different. In the presence of ATP, Puma causes apoptosis by activating Bax/Bak, inducing cytochrome c release, and activating caspases (28, 35, 55, 56) , whereas BNIP3 causes atypical death, instead of apoptosis (14, 26) . The fact that two distinct BH3-only proteins lead to the activation of different types of cardiomyocyte death but the downregulation of either protein makes cardiomyocytes resistant to death suggests a scenario where BH3-only proteins would act in concert by forming a regulatory network. Whether there is any cross talk between Puma and BNIP3 during I/R, however, requires further analysis.
In conclusion, our findings establish Puma as an essential mediator of cardiomyocyte death in response to I/R. Our study, therefore, proposes a link between Puma and I/R-associated myocardial dysfunction. On the basis of the marked resistance of Puma-deficient hearts to I/R, this BH3-only gene holds promise as a potential target for therapeutic intervention. Whether Puma contributes to other clinically relevant diseases associated with ischemia, such as heart failure, diabetic nephropathy, or transplantation-related hypoperfusion of various organs, remains to be elucidated.
